Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 20/20 | 0.58 |
| ▸ | LPAR3 | Q9UBY5 | 10/20 | 0.56 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29908077 | 0.91 | LPAR1 (0.59) | LPAR1LPAR3LPAR2 | |
| SCHEMBL25897737 | 0.88 | LPAR1 (0.56) | LPAR1LPAR3LPAR2 | |
| SCHEMBL25897742 | 0.88 | LPAR1 (0.56) | LPAR1LPAR3LPAR2 | |
| SCHEMBL24867681 | 0.88 | LPAR1 (0.54) | LPAR1LPAR3LPAR2 | |
| SCHEMBL24868048 | 0.87 | LPAR1 (0.51) | LPAR1LPAR3 | |
| SCHEMBL30192247 | 0.87 | LPAR1 (0.51) | LPAR1LPAR3 | |
| SCHEMBL25955272 | 0.86 | LPAR1 (0.55) | LPAR1LPAR3LPAR2 | |
| SCHEMBL14711406 | 0.85 | LPAR1 (0.78) | LPAR1LPAR3LPAR2 | |
| SCHEMBL14711405 | 0.83 | LPAR1 (0.79) | LPAR1LPAR3 | |
| SCHEMBL13195898 | 0.83 | LPAR1 (0.85) | LPAR1LPAR3LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188068-A1 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-06-12 | — | — | US | disclosed |
| EP-4490150-A1 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2025-01-15 | — | — | EP | disclosed |
| EP-4182301-B1 | AMIDO CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARM SPA (IT) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023170025-A1 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-09-14 | — | — | WO | disclosed |
| US-20230250093-A1 | AMIDO CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250093-A1 | AMIDO CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | LPAR1, LPAR2, LPAR3 | LPAR1 1/4885LPAR3 3/4885LPAR2 2/4885 |
| US-20250188068-A1 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | LPAR1, LPAR2, LPAR3 | LPAR1 1/4885LPAR3 3/4885LPAR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.